General form of registration statement for all companies including face-amount certificate companies

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:        
Research and development expenses $ 2,195,991 $ 2,077,329 $ 8,933,314 $ 3,496,796
General and administrative expenses 1,988,259 1,366,229 6,143,527 4,289,831
Total operating expenses 4,184,250 3,443,558 16,176,201 7,786,627
Ratchet share expense     1,099,360 0
Loss from operations (4,184,250) (3,443,558) (16,176,201) (7,786,627)
Other (expense) income:        
Interest expense (5,147)   (6,967) (827,539)
Interest income 336 472 1,870 2,012
Australian research and development incentives 51,243 29,241 313,625 43,666
Change in fair value of embedded features       (203,000)
Change in fair value of warrant liability 20,942   98,394 (1,546,280)
Other income (expense), net 67,374 29,713 406,922 (4,791,584)
Paycheck protection program loan forgiveness       62,500
Loss on extinguishment of convertible notes and convertible notes, related parties       (2,322,943)
Net loss (4,116,876) (3,413,845) (15,769,279) (12,578,211)
Net loss attributable to noncontrolling interests       (74,331)
Deemed dividend on warrant modification   (450,578) (450,578) 0
Net loss attributable to MAIA Biotechnology, Inc. shareholders $ (4,116,876) $ (3,864,423) $ (16,219,857) $ (12,503,880)
Net loss per share        
Net loss per share basic     $ (1.75) $ (2.37)
Net loss per share diluted $ (0.38) $ (0.5) $ (1.75) $ (2.37)
Weighted average common shares outstanding basic 10,977,054 7,752,042 9,276,761 5,278,435
Weighted average common shares outstanding diluted     9,276,761 5,278,435